By John Vandermosten, CFA NYSE: AZTR READ THE FULL AZTR RESEARCH REPORT Over the last month, Azitra, Inc. (NYSE: AZTR) has updated investors on its two leading programs and announced a reverse stock split. The ATR-04 Phase I/II EGFR inhibitor-associated rash program has advanced to cohort 2 after being given Safety Review Committee clearance. The program has also expanded its addressable